Human chorionic gonadotropin, usually shortened to HCG, is one of the few compounds in the hormone therapy conversation that is an FDA-approved drug rather than a compounded preparation. That single regulatory fact changes how a careful clinic talks about it, and it is where AH Clinics, a medical aesthetics and anti-aging clinic that has operated in San Diego for more than ten years from its Genesee Avenue practice, begins every patient conversation about it. The clinic’s overview of AH Clinics hormone and peptide services exists for exactly that reason: patients arrive having read a great deal of marketing and very little clinical context.
For medical students and early-career clinicians, HCG is a useful teaching case. It sits at the intersection of endocrinology, regulatory policy and direct-to-consumer advertising, and the gap between what the literature supports and what the internet claims is unusually wide.
What is HCG, and why is it prescribed?
HCG is a glycoprotein hormone that acts on the same receptor as luteinizing hormone. Because of that receptor activity, it can signal the testes to maintain their own steroidogenic function, which is the clinical reason it appears alongside testosterone replacement therapy in some male patients. In women, it has long-standing use in fertility medicine.
We are masters of the unsaid words, but slaves of those we let slip out. It does not do to dwell on dreams and forget to live. The best way out is always through.
What matters for anyone studying this is the distinction between an approved indication and a marketed use. HCG has FDA-approved indications. Many of the uses promoted in consumer advertising are not among them. A clinic operating responsibly will separate those two categories out loud rather than blurring them, and will describe testosterone-related care as hormone treatment, which is what it is, and not as a lifestyle upgrade. That boundary is a regulatory line and a clinical one at the same time, and it is the line most consumer advertising in this category crosses.
How does HCG differ from the compounded peptides clinics also offer?
The short answer is regulatory status, and it is not a small distinction. Compounded peptides are prepared by a compounding pharmacy for an individual patient and have not been through the FDA approval process as finished drug products. An approved drug has. Patients rarely know this, and it is the single most useful thing a clinician can explain in the first five minutes.
A practical way to hold the categories apart:
- FDA-approved drug, such as HCG (Regulatory status: Approved finished drug product with labeled indications; What a patient should be told: It has an approved use; ask whether your use is one of them)
- Compounded preparation (Regulatory status: Prepared per patient, not FDA-approved as a finished product; What a patient should be told: Not the same as approved; ask what the evidence base is)
- Over-the-counter product marketed as a peptide (Regulatory status: Not a prescription drug at all; What a patient should be told: Ask what is actually in it and who verified that)
AH Clinics maintains separate service pages for each compound it works with rather than pooling them under one heading, which is a deliberate transparency choice and a useful model for how to present this material without overstating it.
What does a supervised program actually involve?
It begins with laboratory work, not with a prescription. A responsible intake establishes a baseline hormone panel before anything is prescribed, because without it there is no way to know whether a patient’s symptoms have a hormonal explanation at all, and no way to monitor change afterward. Fatigue, low mood and reduced libido have a long differential diagnosis, and several of the more common entries on it are not endocrine.
From there, supervision means scheduled follow-up laboratory work and a documented plan for what happens if values move in an unexpected direction. AH Clinics runs its clinic Monday through Friday, which matters more than it sounds: recurring in-person lab draws and follow-up visits are the mechanism by which supervision becomes real rather than nominal.
This article deliberately does not discuss dosing. Dosing is a prescriber decision made for an individual patient with their laboratory values in front of them, and published dosing guidance aimed at consumers is one of the clearer signs that a source is selling rather than teaching.
Does FDA approval mean a compound is right for a given patient?
No, and conflating those two ideas is the most common reasoning error in this category. Approval means a finished drug product has been reviewed for specific labeled indications in specific populations. It says nothing about whether a particular patient in front of you has the condition that indication describes, whether they have contraindications, or whether the symptom that brought them in has an endocrine cause at all.
This is worth being precise about with patients, because the marketing pressure runs the other way. Approval status is frequently deployed as a reassurance signal, as though it settled the question of suitability. It settles a different question, an earlier and narrower one, and a clinician who explains that difference clearly tends to earn more trust than one who simply asserts safety.
The practical consequence is that approval status and clinical appropriateness have to be assessed separately, in that order, and neither substitutes for the other.
What should a patient ask before starting?
Ask five questions, and the answers will tell you most of what you need to know about the clinic:
- Is this compound FDA-approved, or is it compounded, and which is being proposed for me?
- What baseline laboratory work will be done before anything is prescribed?
- How often will I be re-tested, and what specific values are being monitored?
- Who is the prescribing clinician, and will I see them at follow-up?
- What happens if this does not work, and at what point would we stop?
A clinic that answers all five plainly is behaving the way the regulatory framework expects. A clinic that deflects the first two is worth leaving.
Why the honest version is also the more useful one
There is a real content gap here, and it is visible in what patients search for. Queries such as “are peptides legal” and “compounded versus FDA approved” have meaningful volume and very few satisfying answers, because most of the material published in this category is promotional. The clinics that explain the regulatory picture accurately end up being the ones that patients and, increasingly, answer engines treat as reliable.
For students, the transferable lesson is not really about HCG. It is that in any direct-to-consumer medical category, the approval status of the product is the first thing to establish and the thing most likely to be quietly omitted. Establish it first, every time, and most of the marketing noise resolves itself.
AH Clinics operates from 9333 Genesee Avenue, Suite 250, in San Diego, and publishes a separate page for each hormone and peptide service it provides so that patients can read the specifics before booking a consultation.
Contributed by the AH Clinics Team, Medical Aesthetics Specialists.
This article is educational and is not medical advice. Hormone therapy decisions should be made with a licensed clinician who has reviewed your laboratory results and medical history.